1	Title: Risk Factors of Multi-Drug Resistant Tuberculosis among Tuberculosis Patients in
2	Province 3, Nepal: A case-control study
3	Short title: MDR-TB Risk Factors in Nepal
4	Authors: Puspa Acharya ^{1*} , Niraj Bhattarai ² , Bhuban Raj Kunwar ³ , Khem Raj Sharma ⁴ , Vijay
5	Kumar Khanal ⁴ , Birendra Kumar Yadav ⁴
6	Affiliations: ¹ Department of Public Health, Shree Birendra Hospital, Chhauni, Kathmandu,
7	Nepal; ² Nepal Development Society, Kathmandu, Nepal; ³ Department of Anesthesia, Shree
8	Birendra Hospital, Chhauni, Kathmandu, Nepal; ⁴ B.P Koirala Institute of Health Sciences,
9	Dharan, Sunsari Nepal
10	Email address of authors: puspacharyas@gmail.com [P. Acharya], bniraj80@gmail.com
11	[N.Bhattarai], drbrkunwar@yahoo.com [B.R. Kunwar], Khemraja@gmail.com [KR.Sharma],
12	vijay.khanal@bpkihs.edu [VK. Khanal], bkyadav1@gmail.com [BK. Yadav]
13	
14	*Corresponding author: puspacharyas@gmail.com [P. Acharya]
15	
16	Abstract
17 18	Background: Drug-resistant tuberculosis poses a significant threat to global TB control
19	efforts, potentially reversing progress made in reducing TB-related morbidity and mortality.
20	This study aims to identify risk factors for multidrug-resistant TB [MDR-TB] in Province 3,
21	Nepal.
22	
23	Methodology: A case-control study was conducted by matching TB-infected patients
24	undergoing MDR-TB treatment and DS-TB treatment by gender. Data was collected through
25	structured questionnaires and interviews and analyzed using binary logistic regression.
26	
27	Results: Significant risk factors for MDR-TB included Pulmonary Tuberculosis [PTB],
28	previous TB treatment history, close contact with DR-TB patients, and subjective feelings of
29	sadness.
30	
31	Conclusion: The study highlights the importance of prevention measures to break transmission
32	chains and infection control in health facilities. Additionally, it underscores the need for mental
33	hoalth support for Bepatients that has not been certified by peer review and should not be used to guide clinical practice.

34 Keywords: MDR-TB, Risk Factors, Previous Treatment History

35

36 Introduction

37

38 Tuberculosis [TB] is the most common cause of death worldwide and the leading cause of death from a single infectious agent, even exceeding HIV/AIDS. An estimated 10.0 million 39 40 [range, 9.0–11.1 million] people fell ill with TB in 2018; there were 1.2 million TB deaths 41 among HIV-negative people in 2018 and a further 2,51,000 deaths among HIV-positive people(1).In April 1993, the World Health Organization [WHO] declared tuberculosis a public 42 43 health emergency[2]. After defining the nature and size of the global TB problem, WHO 44 introduced the Directly Observed Treatment Short-course [DOTS] as a solution to an 45 emergency[3]. The expanding HIV epidemic and the growth of drug-resistant tuberculosis [DR-TB] further subverted the DOTS strategy, which was hampered by imprecise diagnostic 46 47 tools and passive case detection(4).

Antimicrobial Resistance [AMR] is an increasingly significant threat to public health, and the 48 rise of AMR coincides with the development of TB (5,6). The rise of drug-resistant tuberculosis 49 50 has the potential to reverse progress made to scale back tuberculosis-related morbidity and 51 mortality over the past 20 years. Drug resistance emerges as a result of inadequate tuberculosis 52 treatment, which could be an incorrect combination of tuberculosis drugs, inadequate dose or 53 duration, or irregular drug-taking. These problems can occur in any setting but are particularly prevalent in poorly regulated non-public sectors(7). Multi-drug resistant tuberculosis [MDR-54 55 TB] is tuberculosis that is resistant to at least two first-line drugs, isoniazid and rifampicin(8).TB strains with DR-TB are harder to treat than drug-susceptible ones and also 56 57 take much longer(9). Globally, only half of the MDR-TB patients are treated successfully; the other half are at high risk of either not surviving or continuing to transmit the disease and 58 59 threaten global progress towards the targets set by the End TB Strategy of the World Health Organization [WHO](4). Globally, in 2018, an estimated 3.4% [95% confidence interval [CI]: 60 2.5-4.4%] of new cases and 18% [95% CI: 7.6-31%] of previously treated cases had MDR/RR-61 TB. There were 484,000 [range, 417,000–556,000] incident cases of MDR/RR-TB in 2018, 62 and only 32% of the estimated patients were enrolled in treatment. The highest proportions are 63 in several countries of the former Soviet Union [above 25% in new cases and above 50% in 64 previously treated cases. World Health Organization [WHO] has recently updated the guidance 65 66 on DR-TB treatment by including Levofloxacin [a fluoroquinolone] and pyrazinamide as a 67 component of the treatment regimens for MDR/RR-TB and isoniazid-resistant, rifampicinsusceptible TB [Hr-TB](1). As MDR-TB involves more extensive and longer treatment courses 68 69 than drug-susceptible TB, households with multidrug resistances are at a particularly greater risk of incurring catastrophic costs(10). The percentage facing catastrophic total costs ranged 70 71 from 27% to 83% for all forms of TB and from 67% to 100% for drug-resistant TB (1). The 72 disease can affect anyone anywhere, but most people who develop TB [about 90%] are adults, 73 and the male: female ratio is 2:1[1]; long-term exposure to ambient SO2 is likely to increase 74 the risk of TB in males(11). Global targets and milestones for reducing the burden of TB 75 disease have been set as part of the Sustainable Development Goals [SDGs] and the World Health Organization's End TB Strategy, and seven countries with high TB burdens were also 76 77 on track to achieve 2020 END TB milestones during this period (1).

78

Tuberculosis [TB] remains a serious public health problem in the South-East Asia Region [SEAR] as well (12). DR-TB burden was higher in India [27%], China [14%] and the Russian Federation [9%] in 2018(1).TB is also the leading cause of disability-adjusted life years [DALYs] lost among people in the region among all communicable diseases, affecting the productive age group of the countries in SEAR(13). Similarly, Myanmar has over 70% of TSR for MDR-TB and was on track to achieve 2020 END TB milestones.(1).

85

86 It has been predicted that deaths attributable to AMR could rise more than tenfold to 10 million annually by 2050. Unless action is taken now, DR-TB could be responsible for about 2.5 87 88 million of these deaths(14). A global total of 186 772 cases of multidrug-resistant TB or rifampicin-resistant TB [MDR/RR-TB] were notified in 2018, up from 160 684 in 2017, and 89 90 156 071 cases were enrolled in treatment, up from 139 114 in 2017. Despite these 91 improvements, only 32% of the estimated 484,000 cases [range 417,000-556,000] were 92 enrolled in treatment in 2018(1). The uncontrolled TB burden impacts socio-economic 93 development and increases drug resistance in the SEAR region (15). If tuberculosis management practices across sectors in India remain unchanged over the next 20 years, it is 94 estimated a 47% increase in the incidence of isoniazid resistance, a 152% increase in MDR-95 TB incidence, a 242% increase in prevalent untreated multidrug-resistant tuberculosis, and a 96 275% increase in the risk of multidrug-resistant tuberculosis infection(7). 97

98

In Nepal, there are approximately 1500 [0.84 to 2.4] cases of DR-TB annually, and only 350

100 to 450 MDR-TB cases are reported annually. So, the missing cases are the major problem in 101 Nepal(8). There are major challenges for diagnosis of MDR TB in Nepal, such as inadequate 102 training, frequent power failure, difficulty in maintaining an appropriate steady temperature, 103 module failure, which is often not replaced in time, issues with calibration and timely 104 availability of cartridges, as well as appropriate ways to store the new cartridges and safe disposal of the used cartridges (16). From a public health perspective, the MDR-TB growing 105 106 epidemics will not be controlled merely by the introduction of a few new antibiotics as it is 107 also linked to patient compliance and adequate case management supported by efficient TB 108 programs(17). Deaths from drug-resistant TB now account for about one-third of all 109 antimicrobial resistance deaths worldwide. Treating DR-TB is costlier and may take three to 110 fourfold as long as not all people will survive.(6). The latest treatment outcome data for people 111 with MDR/RR-TB showed a global treatment success rate of only 56%(1).

112 As MDR-TB involves more extensive and longer treatment courses than drug-susceptible TB, households with multidrug resistance are at a particularly greater risk of incurring catastrophic 113 114 costs. The study identified the factors associated with resistance that might assist concerned authorities in focusing efforts on those factors in the community. This might help prevent and 115 116 control tuberculosis and MDR-TB by influencing Public Health Policy. As MDR-TB involves 117 more extensive and longer treatment courses than drug-susceptible TB, households with multidrug resistance are at a particularly greater risk of incurring catastrophic costs. Hence, 118 119 ending TB will benefit the poorest ones.(10). This study aims to assess the risk factors of Multi-120 Drug-Resistant Tuberculosis among Tuberculosis patients of Province 3, Nepal.

121

122 METHODS

123

The study used a case-control design to evaluate the risk of MDR-TB, which was conducted in 124 125 Province 3, Nepal, which is known for its high MDR-TB burden. Cases comprised confirmed 126 MDR-TB patients undergoing treatment at selected MDR treatment centres and sub-centres in Kathmandu, Bhaktapur, and Chitwan. At the same time, controls consisted of TB patients 127 receiving anti-tuberculosis drugs at designated DOTS centres in the same districts. Inclusion 128 129 criteria for cases required confirmation of MDR-TB through records from the MDR-TB treatment center, while controls encompassed pulmonary and extra-pulmonary TB patients on 130 131 anti-tuberculosis medication. Exclusions were applied to severely ill patients who were unable 132 to participate and those under 15 years old. The study adhered to ethical considerations,

133 received clearance from the institutional review committee, and obtained informed verbal consent from respondents, ensuring confidentiality and data integrity. The researcher also took 134 135 permission from the National Tuberculosis Control Centre, Thimi Bhaktapur, to conduct this research in the selected study sites after receiving IRC clearance. The structured questionnaire 136 137 was prepared after a substantial literature review, and a piloting study was done among TB patients of BPKIHs, Dharan, by obtaining verbal consent from the participants. The study was 138 139 conducted from March 2021 to August 2021. The operational definition used in the study is 140 included as a supplementary document.

141

142 Sampling Technique:

143

144 The three districts were selected randomly, and all the DR-TB centres from these districts were included in the study. The subjects who gave consent were interviewed. Cases were selected 145 from these DR-TB treatment centres/subcentre such as Nepal Anti-TB Association-146 147 Kathmandu, Japan Nepal Tuberculosis Research association-Kathmandu, National Tuberculosis Control centre-Bhaktapur, Nepal Anti-TB Association- Chitwan. All the DS-TB 148 149 cases with approved verbal consent were interviewed. DOTS centres such as Manmohan 150 Memorial Medical College and Teaching Hospital-Kathmandu, Nagarik Community Hospital-151 Bhaktapur, Bharatpur Health office, Parbatipur Health Post, Genetup-Kathmandu, JANTRA-152 Kathmandu, NATA-Chitwan were selected for this study.

153

154 Calculation of the sample size:

The study period was fixed for six months, and during the study periods, all the laboratoryconfirmed and registered DR-TB patients were asked to participate from all treatment centres/sub-centres in selected districts—Chitwan, Kathmandu, and Bhaktapur. Despite approximately 85 DR-TB patients across these districts, only 77 agreed to participate. All the DS-TB cases were also interviewed, and gender matching was ensured using SPSS, resulting in a final sample size of 154 respondents, maintaining a 1:1 ratio of cases to controls.

161

162 Data Collection Techniques

163

Amidst the challenges posed by the COVID-19 pandemic, a second wave in Nepal, a face-toface interview was undertaken to collect data from both cases and controls. The clinical

166 attributes of the participants were meticulously validated against their laboratory records. 167 Despite the pandemic's constraints, conducting interviews proved to be difficult. However, the 168 institution provided a designated counselling room, coupled with the use of appropriate 169 personal protective equipment [PPE] and adherence to social distancing measures; data 170 collection was successfully facilitated. Recent episodes of TB history were taken to avoid recall 171 bias, and a researcher collected data herself to minimise interviewer variations.

172

173 Data Management and Analysis

174 Data entry was conducted using Microsoft Excel and subsequently transferred to SPSS version 16 for statistical analysis. Before entry, numerical coding was manually prepared based on the 175 176 nature of the data, and regular cross-checking ensured accuracy, with verification after every 177 ten entries. Descriptive statistics, Frequency, and percentages were employed to present case 178 and control frequencies. The inferential analysis utilised chi-square tests for categorical 179 nominal data association and binary regression analysis for variables potentially predictive of MDR-TB, with significance set at p < 0.05 and 95% confidence intervals. Factors exhibiting a 180 181 p-value less than 0.020 in bivariate analysis underwent binary logistic regression for further 182 analysis after adjusting confounders.

183 Variables of the

184 **study:**

185 Independent variable

186	\checkmark	Age
187		
188	\checkmark	Gender
189		
190	\checkmark	Weight
191		
192	\checkmark	Marital status
193		
194	\checkmark	Residence
195		
196	\checkmark	Education
197		
198	\checkmark	Occupation
199		
200	\checkmark	Monthly income
201		

202 203	\checkmark	Ethnicity
204	\checkmark	Religion
205 206	\checkmark	Family type
207 208	\checkmark	Co- Morbid (HIV/AIDS & Other diseases)
209 210	\checkmark	stigma
211 212	\checkmark	social isolation
213 214	\checkmark	Means of transportation
215 216 217	✓	Subjective feelings of sadness
218 219	Associa	ited factors
220	\checkmark	Types of TB
221 222	\checkmark	Previous History of TB
223 224	\checkmark	Interruption of TB treatment
225 226	\checkmark	Contact with TB patients
227 228	\checkmark	Contact with DR TB patients
229 230	\checkmark	Response to Treatment Phase
231 232 233	\checkmark	Counselling session
234 235	Depend	ent variable
236	\checkmark	Multi Drug Resistant Tuberculosis (MDR-TB)
237		
238 239	RESUL	ATS
240	Table 1 il	lustrates demographic and socio-economic characteristics between cases and controls.
241	While bo	oth groups have similar gender distributions, with males representing 55.8% and
242	females 4	4.2%, the control group has a higher proportion of individuals under 35 years [64.9%]
243	compared	to the case group [58.4%]. Marital status and ethnicity are largely comparable, but

there are differences in residence, education, and employment status. The control group has

245 more residents in metropolitan cities [62.3% vs. 41.6% in cases] and fewer in rural areas

- 246 [13.0% vs. 37.7% in cases]. Additionally, a higher percentage of cases are unemployed [44.2%
- vs. 33.8% in controls] and more are students [24.7% vs. 31.2% in controls]. Access to health
- facilities within 30 minutes is higher in the control group [96.1% vs. 66.2% in cases], and they
- 249 utilize private health facilities more [85.7% vs. 58.8% in cases].
- 250 Table 1: Demographic and Socio-economic characteristics of respondents.

	Case [n=77]	Percentage	Control [n=77]	Percentage
Characteristics	Frequency [n]	[%]	Frequency [n]	[%]
Age				
< 35	45	[58.4%]	50	[64.9%]
≥35	32	[41.6%]	27	[35.1%]
Gender	·			
Male	43	[55.8%]	43	[55.8%]
Female	34	[44.2%]	34	[44.2%]
Marital status	·	-	·	
Unmarried	32	[41.60%]	35	[45.50%]
Married	43	[55.80%]	41	[53.20%]
Widow	1	[1.30%]	1	[1.30%]
Widower	1	[1.30%]	0	[0.00%]
Residence	•			
Metropolitan city	32	[41.6%]	48	[62.3%]
Municipality	16	[20.8%]	19	[24.7%]
Rural Municipality	29	[37.7%]	10	[13.0%]
Education	·	-	·	
Uneducated	5	[6.5%]	5	[6.5%]
Primary level	22	[28.6%]	13	[16.9%]
Secondary level	20	[26.0%]	28	[36.4%]
Higher level education	30	[39.0%]	31	[40.3%]
Occupation				
Unemployed	34	[44.2%]	26	[33.8%]
Formal sector	10	[13.0%]	15	[19.5%]
employee				
Informal sector	14	[18.2%]	12	[15.6%]
employee				
Student	19	[24.7%]	24	[31.2%]
Monthly Income of en	nployed respon	dents [n= 51]		-
< Rs 24000	12	[50%]	15	[55.6%]
≥ Rs 24000	12	[50%]	12	[44.4%]
Ethnicity				
Dalit	2	[2.6%]	4	[5.2%]
Janajati	41	[53.2%]	41	[53.2%]
Madhesi	2	[2.6%]	1	[1.3%]
Muslim	3	[3.9%]	1	[1.3%]
Brahmin/Chhetri	29	[37.7%]	29	[37.7%]

Others	0	[0.0%]	1	[1.3%]
Religion				
Hindu	57	[74.0%]	65	[84.4%]
Buddhist	17	[22.1%]	8	[10.4%]
Muslim	3	[3.9%]	1	[1.3%]
Christian	0	[0.0%]	3	[3.9%]
Family Type				
Nuclear	39	[50.60%]	46	[59.70%]
Joint	36	[46.80%]	30	[39.00%]
Extended	2	[2.60%]	1	[1.30%]
Presence of Adequate	Ventilation			
No	20	[25.9%]	8	[10.3%]
Yes	57	[74.1%]	69	[89.7%]
Recent Migration				
No	35	[45.5%]	50	[64.9%]
Yes	42	[54.5%]	27	[35.1%]
Types of Migration				
Internal Migration	37	[88.1%]	23	[85.2%]
External Migration	5	[11.9%]	4	[14.8%]
Time to reach Health	Facilities			
Less than 30 minutes	51	[66.2%]	74	[96.1%]
Greater than 30	026	[33.8%]	3	[3.9%]
minutes				
Means of Transporta	ition			
Cycle	1	[1.3%]	2	[2.6%]
Bike/Scooter	11	[14.3%]	25	[32.5%]
Public Vehicle	64	[83.1%]	41	[53.2%]
By foot	1	[1.3%]	9	[11.7%]
Health-seeking Behav	vior of patients			
Too late	57	[74.0%]	51	[66.2%]
In time	171	[22.1%]	25	[32.5%]
Early	3	[3.9%]	1	[1.3%]
Treatment Initiation	site			
Public Health Facilitie	s43	[58.8%]	11	[14.3%]
Private Health	n34	[42.2%]	66	[85.7%]
Facilities				

251

Table 2 shows that pulmonary TB cases were higher among the cases, at 89.6%, compared to 252 253 57.1% in the control group. Conversely, Extra Pulmonary TB cases were more prevalent in the Controls at 42.9% versus 10.4% in the Cases. Notably, a prior history of TB was significantly 254 more common among Cases, with 63.6% compared to a mere 10.4% in Controls. Among those 255 256 with a TB history, Cases experienced treatment interruptions at a higher rate of 51.0%, contrasting with just 12.5% in Controls. Reasons for such interruptions varied, with 257 258 complications accounting for 8% among Cases and none among Controls, while loss to followup stood at 16% for Cases versus 100% for Controls. Additionally, 25% of Cases switched to 259

260 MDR treatment compared to none in Controls. Close contact with TB patients was markedly more prevalent among Cases [64.9%] than Controls [32.5%], with similar trends observed for 261 262 contact with DR TB patients. Notably, negative sputum conversion rates were higher among Cases [79.2%] versus Controls [66.2%]. Hospital stays were significantly more common 263 264 among Cases [89.6%] than Controls [31.2%]. Treatment modalities also exhibited disparities, 265 with 44.2% of Cases receiving treatment after failure compared to none in Controls and 48.1% 266 of Cases undergoing the intensive treatment phase versus 74.0% of Controls. In terms of TB 267 treatment categories, Cases predominantly fell into LR1 [58.5%] and LR2 [31.1%] categories,

- while Controls were exclusively categorized as CAT I [100%].
- 269 Table 2: Clinical Characteristics of Respondents

Characteristics	Case[n=77] Frequency	Percentage [%]	Control[n=77] Frequency	Percentage [%]
Tuberculosis Type	¥¥		requency	
Pulmonary TB	69	[89.6%]	44	[57.1%]
Extra Pulmonary T	B8	[10.4%]	33	[42.9%]
Previous history o				
No	28	[36.4%]	69	[89.6%]
Yes	49	[63.6%]	8	[10.4%]
If yes, was there a	ny interruption	of TB treatment [n= 49 cases, 8 c	ontrols]
No	24	[49.0%]	7	[87.5%]
Yes	25	[51.0%]	1	[12.5%]
Reason for interru	uption of TB tre	atment [n= 25 cas	es, 1 controls]	
Complication	2	[8%]	0	[0%]
Loss to follow up	4	[16%]	1	[100%]
Switch to MDR	5	[25%]	0	[0%]
Site Changed	1	[4%]	0	[0%]
TAF	12	[48%]	0	[0%]
Workload	1	[4%]	0	[0%]
Close contact with	TB Patients			
No	27	[35.1%]	52	[67.5%]
Yes	50	[64.9%]	25	[32.5%]
Close contact with	DR TB patient	ts	·	
No	38	[49.4%]	76	[98.7%]
Yes	39	[50.6%]	1	[1.3%]
Response to TB tr	eatment [Sputu	m Conversion]		
Negative	61	[79.2%]	51	[66.2%]
Positive	16	[20.8%]	26	[33.8%]
Experience of hos	pital stays			
No	8	[10.4%]	53	[68.8%]
Yes	69	[89.6%]	24	[31.2%]
Registration categ				
New	23	[29.9%]	69	[89.6%]
Relapse	26	[20.8%]	8	[10.4%]
Treatment Aft	er			

Failure	34	[44.2%]	0	[0.0%]
Treatment after loss				
to follow-up	2	[2.6%]	0	[0.0%]
Others previously	r			
Treated	1	[1.3%]	0	[0.0%]
Previous Treatment	-			
History Unknown	1	[1.3%]	0	[0.0%]
Treatment Phase				
Intensive	37	[48.1%]	57	[74.0%]
Continuous	40	[51.9%]	20	[26.0%]
TB Treatment Cate	gory			_
LR1	45	[58.5%]	0	[0%]
LR2	24	[31.1%]	0	[0%]
LR3	1	[1.3%]	0	[0%]
SSTR	4	[5.2%]	0	[0%]
Others	3	[3.9%]	0	[0%]
CAT I	0	[0%]	77	[100%]

270

271 Table 3 presents psychological and social tuberculosis-related variables [TB] among cases and 272 controls. In the cases group, 54.5% attended TB counselling sessions, which was notably 273 higher than 85.7% in the control group. Regarding HIV status, 93.5% of Cases were negative, compared to 100% of Controls. Additionally, 31.2% of Cases reported having other diseases, 274 275 contrasting with 24.7% in the control group. Alcohol consumption was notably prevalent among Cases at 76.6%, whereas 68.8% of Controls reported the same. Smoking was more 276 277 common among Cases [51.9%] than in Controls [18.2%], and similarly, illicit drug use was higher in Cases [18.2%] than in Controls [2.6%]. The incidence of imprisonment was minimal 278 279 in both groups, with Cases slightly higher at 3.9% compared to Controls at 2.6%. Social 280 isolation was more pronounced among Cases at 53.2% compared to Controls at 39.0%. Cases 281 also reported higher rates of perceived stigma associated with TB, with 74.0% fearing loss of 282 friends and employment, 77.9% experiencing social stigma, and 55.8% preferring privacy 283 regarding their TB status, whereas Controls reported lower rates in these categories. 284 Furthermore, Cases exhibited higher nervousness levels [76.6%] and sadness [58.4%] than Controls. Troubles within the past 12 months were reported by 46.8% of Cases and 14.3% of 285 Controls. Despite challenges, both groups expressed happiness, with 79.2% of Cases and 286 287 88.3% of Controls considering themselves happy despite their TB status.

288 Table 3: Psychological and co-morbidity status of respondents

	Case [n=77]	Percentage	Control [n=77]	Percentage				
Variables	Frequency [n]	[%]	Frequency [n]	[%]				
Attended a	Attended any TB counselling sessions							
No	35	[45.50%]	11	[14.30%]				

Yes	42	[54.50%]	66	[85.70%]
HIV stat	us			J
Negative	72	[93.5%]	77	[100.0%]
Positive	5	[6.5%]	0	[00.0%]
Presence	of other disease	_		
No	53	[68.8%]	58	[75.3%]
Yes	24	[31.2%]	19	[24.7%]
Alcohol c	onsumption			
No	18	[23.4%]	24	[31.2%]
Yes	59	[76.6%]	53	[68.8%]
Smoking				<u> </u>
No	37	[48.1%]	63	[81.8%]
Yes	40	[51.9%]	14	[18.2%]
llicit dru	ig use			
No	63	[81.8%]	75	[97.4%]
Yes	14	[18.2%]	2	[2.6%]
[mprison	ment			
No	74	[96.10%]	75	[97.40%]
yes	3	3 [3.90%]	2	[2.60%]
Social iso	lation			
No	36	[46.8%]	30	[39.0%]
Yes	41	[53.2%]	47	[61.0%]
feel tha	t I will lose friends and er	nployment b	ecause I have TB	
No	20	[26.0%]	55	[71.4%]
Yes	57	[74.0%]	22	[28.6%]
People lo	ok at me differently beca	use I have tu	berculosis	
No	17	[22.1%]	49	[63.6%]
Yes	60	[77.9%]	28	[36.4%]
don't li	ke other people to know t	hat I have T	B	
No	34	[44.2%]	24	[31.2%]
Yes	43	[55.8%]	53	[68.8%]
	r myself nervous			
No	18	[23.4%]	41	[53.2%]
Yes	59	[76.6%]	36	[46.8%]
Sometim	es I feel so sad that nothir	ng can cheer	me up	
No	32	[41.6%]	68	[88.3%]
Yes	45	[58.4%]	9	[11.7%]
Did some	thing trouble you during		nonths?	
No	41	[53.2%]	66	[85.7%]
Yes	36	[46.8%]	11	[14.3%]
	f disease, I think I am ha		-	J
No	16	[20.80%]	16	[11.70%]
Yes	61	[79.20%]	61	[88.30%]

Table 4 shows several significant associations highlighting key environmental and socioeconomic factors. Cases group exhibit a notably higher prevalence in rural areas, with 37.7%residing in rural municipalities compared to only 13.0% of controls [p = 0.02]. Recent

293 migration emerges as a significant factor, with 54.5% of Cases reporting recent migration compared to 35.1% of controls [p = 0.015]. Additionally, inadequate ventilation is more 294 295 prevalent among the cases group, with 26.0% reporting inadequate ventilation compared to 10.4% of controls [p = 0.012]. Access to healthcare services is also impacted, as evidenced by 296 297 66.2% of cases taking more than 30 minutes to reach health facilities compared to only 3.9% of controls [p < 0.001]. These findings underscore the critical influence of environmental and 298 299 socio-economic determinants on TB prevalence and access to healthcare, emphasizing the 300 importance of targeted interventions to address these disparities for effective TB prevention 301 and control strategies.

- Р Characteristics Control[n=77] Case[n=77] Frequency [%] Frequency [%] value Age 0.407 <35 45 [58.4%] 50 [64.9%] 32 [41.6%] 27 [35.5%] \geq 35 Gender 43 [55.8%] 43 [55.8%] 1.000 Male Female 34 [44.2%] 34 [44.2%] Marital status 32 [41.60%] 35 [45.50%] Unmarried Married 0.468 43 [55.80%] 41 [53.20%] Widow 1 [1.30%] 1 [1.30%] Widower 1 [1.30%] 0 [0.00%] Residence Metropolitan city 32 [41.6%] 48 [62.3%] 16 [20.8%] 19 [24.7%] 0.02 Municipality Rural Municipality 10 [13.0%] 29 [37.7%] Education Uneducated 5 [6.5%] 5 [6.5%] 0.30 22 [28.6%] Primary level 13 [16.9%] Secondary level 20 [26.0%] 28 [36.4%] Higher level education 30 [39.0%] 31 [40.3%] Occupation Unemployed 34 [44.2%] 26 [33.8%] Formal sector employee 0.591 10 [13.0%] 15 [19.5%] Informal sector employee 14 [18.2%] 12 [15.6%] student 19 [24.7%] 24 [31.2%] Ethnicity Brahmin/Chhetri 29 [37.7%] 29 [37.7%] 1.000 Others 48[62.3%] 48[62.3%] Religion 57 [74.0%] 65 [84.4%] 0.112 Hindu Non-Hindu 20 [26.0%] 12 [15.6%] Family Type
- **302** Table 4 : Key Factors associated with MDR-TB

60%] 46 [59.70%] 80%] 30 [39.00%] 0%] 1 [1.30%] 0%] 8 [10.4%] 0%] 8 [10.4%] 0%] 60 [900%]	
%] 1 [1.30%] 0%] 8 [10.4%] 0.012	
0%] 8 [10.4%] 0.012	
A A	
A A	
00/1 (0.000/1	
0%] [89%]	
5%] 50 [64.9%] 0.015	
5%] 27 [35.1%]	
1%] 23 [85.2%] 0.729	
%] 4 [14.8%]	
2%] 74 [96.1%] <0.001	1
8%] 3 [3.9%]	
6] 2 [2.6%] 0.060	
3%] 25 [32.5%]	
1%] 41 [53.2%]	
6] 9 [11.7%]	
0%] 51 [66.2%] 0.53	
1%] 25 [32.5%]	
6] 1 [1.3%]	
	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$

303

304 Table 5 depicted Pulmonary TB as notably more prevalent among cases [89.6%] compared to 305 controls [57.1%], indicating it as a significant risk factor [p < 0.001; OR: 6.5; 95% CI: 2.7-15.2]. Conversely, controls exhibited a higher incidence of Extra Pulmonary TB [42.9%] 306 307 compared to cases [10.4%]. Individuals with a previous TB history were notably more common 308 among cases [63.6%] than controls [10.4%], indicating it as a substantial risk factor [p < 0.001; OR: 15.09; 95% CI: 6.34-35.91]. Similarly, cases were more likely to report close contact with 309 310 TB patients [64.9%] compared to controls [32.5%], showing a significant association $[p < p_{1}]$ 0.001; OR: 3.85; 95% CI: 1.97-7.51] likewise, cases were significantly associated with close 311 contact with drug-resistant TB patients [p = 0.001; OR: 78; 95% CI: 10.31-589.62] suggesting 312 the exposure as a risk factor. Cases reported higher levels of perceived stigma, with concerns 313 about losing friends and employment due to TB [p < 0.001; OR: 7.12; 95% CI: 3.50-14.49] 314 315 and feeling that people looked at them differently [p < 0.001; OR: 6.17; 95% CI: 3.02-12.57], indicating poor psychosocial health. Additionally, cases exhibited a higher prevalence of 316 317 nervousness [p < 0.001; OR: 3.73; 95% CI: 1.86-7.45] and consistent sadness [p < 0.001; OR: 10.62; 95% CI: 4.63-24.36], signifying these as factors of concern. These findings highlight 318 the importance of addressing these psychosocial risk factors alongside medical interventions 319

320 in TB management.

321 Table 5: Association of MDR–TB with clinical characteristics of the respondents

322

Catagoniag	Case[n -77]	Control [n-77]	P-	OR	95% CI
Categories	Case[n=77]	Control [n=77]	value	UK	[Lower-Upper]
Tubaraulasis Turas			value		[Lower-Opper]
Tuberculosis Types	60 [90 60/]	44 [57.1%]			
Pulmonary TB	69 [89.6%]	<u>44 [37.1%]</u> 33 [42.9%]	<0.001	6.5	27152
Extra Pulmonary TB	08 [10.4%]	55 [42.9%]	<u>\0.001</u>	0.5	2.7-15.2
Previous history of TI		09 [10 40/]			
Yes	49 [63.6%]	08 [10.4%]	-0.001	15.00	6 24 25 01
No	28 [36.4%]	69 [89.6%]	< 0.001	15.09	6.34-35.91
If yes, was there any i					
Yes	25 [51.0%]	01 [12.5%]		7 20	0.02.62.70
No	24 [49.0%]	07 [87.5%]	0.059	7.29	0.83-63.70
Close contact with TB			1	1	
Yes	50 [64.9%]	25 [32.5%]			
No	27 [35.1%]	52 [67.5%]	< 0.001	3.85	1.97-7.51
Close contact with Dr	<u> </u>			1	1
Yes	39 [50.6%]	01 [1.3%]			
No	38 [49.4%]	76 [98.7%]	0.001	78	10.31-589.62
Response to TB treatr		1	1	1	1
Positive	16 [20.8%]	26 [33.8%]			
Negative	61 [79.2%]	51 [66.2%]	0.07	0.51	0.24 -1.06
Experience of hospital	l stays				
Yes	69 [89.6%]	24 [31.2%]			
No	08 [10.4%]	53 [68.8%]	< 0.001	19.04	7.92-45.76
Attended any TB cour	nselling session	S			
Yes	42 [54.50%]	66 [85.70%]			
No	35 [45.50%]	11 [14.30%]	< 0.001	5	2.29-10.90
HIV status				-	
Positive	5 [6.5%]	0 [0.0%]			
Negative	72 [93.5%]	77[100.0%]	0.02	_	
Presence of other dise				_1	
Yes	24 [31.2%]	19 [24.7%]			
No	53 [68.8%]	58 [75.3%]	0.36	1.38	0.68-2.80
Alcohol Consumption					
Yes	59 [76.6%]	53 [68.8%]			
No	18 [23.4%]	24 [31.2%]	0.278	1.48	0.72-3.03
Smoking					
Yes	40 [51.9%]	14 [18.2%]			
No	37 [48.1%]	63 [81.8%]	< 0.001	4.86	2.34-10.11
Illicit Drug					
Yes	14 [18.2%]	2 [2.6%]			
No	63 [81.8%]	75 [97.4%]	0.002	8.33	1.82-38.06
Imprisonment	05 [01.070]		0.002	0.55	1.02 50.00
Yes	3 [3.90%]	2 [2.60%]			
No	<u> </u>	75 [97.40%]	1.00	1.52	0.24-9.36
INU	/4 [90.10%]	[13 [91.4070]	1.00	1.34	0.24-9.30

Social Isolation	1	1	1	1	1
Yes	41 [53.2%]	47 [61.0%]	0.329	0.72	0.38-1.37
No	36 [46.8%]	30 [39.0%]			
I feel that I will lose fri	ends and empl	loyment because I	have T E	3	
Yes	57 [74.0%]	22 [28.6%]	< 0.001	7.12	3.50-14.49
No	20 [26.0%]	55 [71.4%]			
People look at me diffe	rently because	I have tuberculos	is.		
Yes	60 [77.9%]	28 [36.4%]	< 0.001	6.17	3.02-12.57
No	17 [22.1%]	49 [63.6%]	1		
I don't like other peopl	e to know that	t I have TB		•	
Yes	43 [55.8%]	53 [68.8%]	< 0.001	0.57	0.29-1.10
No	34 [44.2%]	24 [31.2%]			
I consider myself nervo	ous.			•	
Yes	59 [76.6%]	36 [46.8%]	< 0.001	3.73	1.86-7.45
No	18 [23.4%]	41 [53.2%]			
Sometimes, I feel so sad	d that nothing	can cheer me up			
	45 [58.4%]	9 [11.7%0	< 0.001	10.62	4.63-24.36
No	32 [41.6%]	68 [88.3%]	1		
Did something trouble	you during the	e past 12 months?		•	
Yes	36 [46.8%]	11 [14.3%]	< 0.001	5.26	2.41-11.48
No	41 [53.2%]	66 [85.7%]			
Despite of disease, I thi	nk I am happy	y.			
Yes	61 [79.20%]	68 [88.30%]	0.126	1.98	0.81-4.81
No	16 [20.80%]	9 [11.70%]			

323

324 After adjusting for the confounding factors, the final regression model [Table 6] showed that 325 subjects infected with pulmonary tuberculosis were 14 times more at risk for MDR-TB than 326 respondents with Extrapulmonary. Respondents who had previous TB treatment history were found to have more than 5-fold risk for MDR TB than those who were not previously treated. 327 328 Similarly, respondents who were in close contact with DR-TB patients were found to be almost 22 times the risk for MDR-TB. In addition, MDR-TB patients were more [OR= 42.33, CI 1.36-329 330 1315.4] likely to perceive subjective feeling of sadness. Cases $[Y] = \beta 0 + \beta 1 [PTB] + \beta 2 [PH] + \beta 3 [DR-TB-C] + \beta 4 [sad] Y = [-5.342] + 2.6 + 1.622 + 1.62$ 331

332 3.099 + 3.746

333 Y= 5.725

334

This equation showed that one unit change in independent variables causes a 5.725 times change in dependent variables.

337 Table 6 Multivariate analysis of factors associated with MDR TB

					95% C.I. for OR	
Variables	Cat	β	-	Odds Ratio	Lower	Upper
			value			

Tuberculosis Type	EPTB**	Ref.				
	РТВ	2.69	0.004	14.7	2.321	93.54
Previous TB treatment	No **					
History						
	Yes	1.622	0.046	5.06	1.03	24.87
Close contact with DR	No**					
TB patients						
	Yes	3.099	0.015	22.18	1.829	269.1
Sometimes, I feel so sad	No**					
that nothing can cheer	Yes	3.746	0.033	42.35	1.364	1315.4
me up						
Constant		-5.342	0.013	0.005		

338

339 **: Reference, Cat: Categories, N= 154

340

341 **Discussion**

342

The study has provided relevant information about factors associated with MDR-TB, which can support activities being implemented to decrease the burden of TB in Nepal for policymakers. This study showed that Pulmonary Tuberculosis type, previous TB treatment history, close contact with DR-TB patients and subjective feelings of sadness were the strong predictors for MDR-TB.

348

349 Among sociodemographic factors, we identified that people residing in rural municipalities are 350 more likely to develop MDR-TB than those living in urban areas [p=0.02], as supported by other studies(18,19). These data are alarming given the geographical features of our country 351 352 like Nepal. Whereas the study conducted in Ukraine showed that the prevalence of RR/MDR-TB in the rural population was significantly lower than in the urban population at 20.9% and 353 354 29.0%, respectively [P = 0.000](20). This study also showed migration as one of the risk factors of MDR-TB [P = 0.015, OR = 2.22, 95% CI 1.16-4.25]. The study conducted in China showed 355 356 that MDR is more prevalent among migrants [odds ratios [OR] 1.32, 95% confidence interval 357 [CI] 1.02–1.72](21); migration is considered an important contributor to missing cases and may 358 lead to poor outcomes(22). To mitigate the number of migrants, it's essential to ensure uniform standards of care accessible nationwide, facilitated by robust communication channels such as 359 360 telemedicine and referral systems. Additionally, implementing a unique identifier system 361 would enable seamless patient connectivity across provinces and the entire nation.

362

363 This study showed that inadequate ventilation at home was a risk factor for MDR-TB [p = 0.01]. Poor ventilation and overcrowding have been documented as a risk factor for MDR-TB 364 365 in several other studies in a variety of settings as well(23,24). Likewise, those subjects who 366 lived in a house with no window or one window were almost two times more likely to develop 367 airborne infection compared to people whose house has multiple windows [AOR = 1.81; 95% CI:1.06, 3.07](25), which may be due to the availability of favourable environment for MDR-368 369 TB transmission. Therefore, advocating for adequate ventilation is crucial to disrupt the 370 transmission chain of MDR-TB.

371 Our study showed clinical features such as types of TB, previous TB treatment history, close 372 contact with TB and DR-TB patients, and experience of hospital stays as the risk factors of 373 MDR-TB with p = 0.001 for each factor. The majority of cases [89.6%] and controls [57.1%] 374 had Pulmonary Tuberculosis, which is similar to the study conducted in Ethiopia, with the majority of participants having pulmonary TB in cases 141 [92.2%] and controls 137 [89.5%] 375 376 (26). We found that patients having Pulmonary Tuberculosis were more likely to develop MDR-TB than those of Extra pulmonary TB patients, which is statistically significant in the 377 378 final binary logistic regression model with OR = 14.735, 95% CI [2.321-93.54], as confirmed 379 by the different studies in different countries; Germany(27), India(28) and Thailand(29).

380

381

382 This study showed previous TB treatment history was strongly associated with MDR-TB in final regression model, with OR= 5.601 [95% CI, 1.03-24.876]. The increased proportion of 383 384 MDR-TB among previously treated cases has been indicated in various studies of various settings(28–33); The rise in MDR-TB cases among previously treated individuals underscores 385 386 the urgency for higher quality treatment to prevent the development of drug resistance. Our 387 study showed that, 51.0% of MDR cases had interruption of TB treatment, which is similar to 388 the study conducted by Sanju B et al in 2017(34). We found patients with Interruption in TB 389 treatment were more likely to develop MDR-TB than those without TB-Treatment interruption [p= 0.059, OR= 7.292, 95%CI 0.83-63.79], and another study also confirmed interruption of 390 treatment as a risk factors of MDR-TB [28,35–38]. Interruption of TB treatment promotes the 391 392 risk of bacterial mutations that eventually culminate in relapses and MDR-TB.

Our study showed that 64.9% of cases had history of contact with TB patient. Those who had history of close contact with TB patients were more likely to develop MDR-TB than those without close contact [p<0.001, OR=3.85, CI 1.974-71.5]. Several study conducted in different settings also confirmed that close contact with TB patients is a risk factors of MDR-

397 TB[31,34,39], which is contrast to the study conducted in Ethiopia(40).

398 Similarly, Close contact with DR-TB patients was found to be a risk factor of MDR-TB. Final 399 regression model indicated that close contact with DR-TB patients increase the risk of MDR-400 TB by 22.183 times [OR= 22.183,95% CI,1.829-268.12]. several studies documented close 401 contact with DR-TB as the major risk factors of MDR-TB(37,41,42), which is contrast to the 402 study conducted in Serbia (43). Our study showed that experience of hospital stays as a risk 403 factor of MDR-TB [p = 0.001] ie, patient who had hospitalization history were more likely to 404 develop MDR-TB than those who do not have previous history of hospital stay [p < 0.001,405 OR= 19.047, 95% CI, 7.92-45.76], which is also documented in other studies(25,44). The 406 study conducted by v. Crudu et al documented that in 75% of cases, the MDR-TB strain was 407 genetically distinct from the non-MDR-TB strain at baseline, suggesting a high rate of 408 nosocomial transmission of MDR-TB(40). Proper infection control measures in health facilities 409 are crucial to protect other patients and healthcare workers, whereas preventive measures to 410 reduce transmission within community is required.

411

430

412 This study showed that not attending TB counselling sessions [p < 0.001, OR = 5, 95% CI 2.92-413 10.90] is the risk factor for MDR-TB. One of the studies concluded that the Provision of 414 counselling and financial support may not only reduce their vulnerability but also increase cure 415 rates of MDR-TB(45). This study showed that smokers were more likely to develop MDR-TB 416 than non-smokers [p<0.001, OR=4.8, 95%CI 2.34-10.11], as confirmed by other studies 417 conducted in a different setting, china (46,47), Ethiopia(48), Lima Peru(49), Sudan(50), which 418 is a contrast to the study conducted in Addis Ababa (36), Nepal(51). Smoking had also affected 419 the global TB treatment success rate as shown in the study[65]. This study showed illicit drug 420 use as the risk factor of MDR- TB [P = 0.002, OR = 8.33, 95%CI 1.82-38.06], which is in 421 contrast to the study conducted in Canada(52) and Ethiopia(40). Engaging in illicit drug use 422 and smoking can disrupt the balance of the immune system, potentially heightening 423 susceptibility to infection.

This study showed that, stigma associated with TB as a risk factors of MDR-TB [p <0.001,
OR=0.72, 95%CI 0.38-1.37], which is similar to the study conducted in Serbia(43), china(47),
Nepal(45). It's imperative to safeguard and defend the rights of all individuals with
tuberculosis, as well as those most vulnerable to contracting the disease, Implementing policies
and practices aimed at shielding them from stigmatization and discrimination is essential(4).
There was significant difference in mental health of the respondents, this study showed

Significant difference between the both groups in persistence of subjective feeling of

431 nervousness [P < 0.001, OR=3.77, 95%CI 1.86-7.45], persistence of subjective feeling of 432 sadness [p < 0.001, OR=42.33, CI 1.36-1315.4] and experience of difficult situations in last 433 12 months [p < 0.001, OR=5.26 [2.416-11.488], which is similar to the study conducted in 434 Serbia (43). The study conducted in china also showed experience more life pressure/stress 435 [AOR, 10.8; 95% CI, 2.8–41.5] as the risk factors of MDR-TB(23)A life rejuvenation program 436 tailored for tuberculosis patients in high-risk areas is imperative. As the study covers a large 437 number of DR-TB cases in Nepal during the study period, the findings can be generalized.

438

439 Strengths and Limitation

440

Strengths of the study include collecting information on recent episodes of previous TB 441 442 treatment aimed at minimising recall bias. However, a notable limitation is the absence of data on additional treatment episodes, particularly concerning patients with multidrug-resistant 443 444 tuberculosis [MDR-TB] who often undergo multiple treatments. Additionally, while the study successfully achieved its objectives, it did not employ multiple data-gathering methods to 445 446 explore sensitive topics such as stigma and mental health issues. Notably, this study represents 447 the first attempt to investigate the risk factors of multidrug-resistant tuberculosis in three 448 districts of province number 3, which harbours the highest burden of DR-TB cases in Nepal, favouring generalisation of findings. 449

450

451 CONCLUSION

452

453 This case-control study delved into factors associated with MDR-TB occurrence, identifying 454 Pulmonary Tuberculosis, prior TB treatment history, close contact with DR-TB patients, and 455 persistent subjective feelings of sadness as strong risk factors. The findings underscore the 456 necessity for quality treatment coupled with attentive monitoring to curb drug resistance 457 evolution among previously treated patients. Preventive measures should emphasize breaking 458 transmission chains within communities, bolstered by robust infection control measures in 459 healthcare facilities to minimize acquired MDR-TB cases among visitors, patients, and health 460 workers. Additionally, the study underscores the pressing need for life rejuvenation programs targeting tuberculosis patients to safeguard their mental well-being. 461

462

463 List of abbreviations

464 AMR : Anti-Microbial Resistance, AOR : Adjusted Odds Ratio, BPKIHS : B.P. Koirala

465 Institute of Health Sciences, CAT-I : Category I, CI : Confidence Interval, COPD : Chronic Obstructive Pulmonary Diseases, DOTS : Directly Observed Treatment Short 466 467 Course, DR-TB : Drug-Resistant Tuberculosis, DST : Drug Susceptibility Test, DS-TB : 468 EPTB : Extra Pulmonary Tuberculosis, Drug-Susceptible Tuberculosis, HF : Health 469 Facility. HIV/AIDS : Human Immunodeficiency Virus/Acquired Immunodeficiency 470 HR : Isoniazid, Rifampicin, HRZE : Isoniazid, Rifampicin, Pyrazinamide, Syndrome, 471 Ethambutol, HRZELfx : Isoniazid, Rifampicin, Pyrazinamide, Ethambutol, Levofloxacin, 472 JANTRA : Japan Nepal Health and Tuberculosis Research Association, LPA : Line Probe 473 Assay, LR-1 : Longer Regiment I, LR-2 : Longer Regiment II, LR-3 : Longer Regiment 474 III, LTBI : Latent Tuberculosis Infection, M. Tuberculosis : Mycobacterium Tuberculosis, 475 MDR-TB : Multi-Drug-Resistant Tuberculosis, MDR/RR-TB : Multi-Drug-Resistant 476 Rifampicin-Resistant Tuberculosis, NATA : Nepal Anti Tuberculosis Association, NTC : 477 National Tuberculosis Center, OR : Odds Ratio, PLS-PM : Partial Least Square Path 478 Modelling, PTB : Pulmonary Tuberculosis, RR/MDR : Rifampicin-Resistant/Multi-Drug-Resistant, SDG : Sustainable Development Goals, SEAR : South East Asia Region, SPSS 479 480 : Statistical Package for the Social Sciences, SSTR : Shorter Standardized Treatment 481 Regimen, TB : Tuberculosis, TPT : Tuberculosis Preventive Therapy, TSR : Treatment 482 Success Rate, WHO : World Health Organization, XDRTB : Extremely Drug-Resistant 483 Tuberculosis

484

485 Acknowledgements

486 The authors would like to acknowledge Dr Suvesh Kumar Shrestha for his valuable insights487 and sincerely thank all the participants.

488

489 Author's contribution

- 490 Conceptualisation: Puspa Acharya, Niraj Bhattarai, Vijay Kumar Khanal
- 491 Data curation: Puspa Acharya, Niraj Bhattarai , Dr Bhuban Raj Kunwar ,Birendra Kuma
 492 Yadav,
- 493 Formal analysis: Puspa Acharya, Niraj Bhattarai, Khem Raj Sharma
- 494 Methodology: Puspa Acharya, Niraj Bhattarai, Dr Bhuban Raj Kunwar
- 495 Supervision: Vijay Kumar Khanal, Birendra Kuma Yadav, Khem Raj Sharma , Dr Bhuban
- 496 Raj Kunwar
- 497 Validation: Vijay Kumar Khanal, Birendra Kuma Yadav, Khem Raj Sharma, Dr Bhuban Raj

498	Kunw	ar				
499	Writi	Writing original draft: Puspa Acharya, Niraj Bhattarai				
500	Writi	Vriting-review and editing: Puspa Acharya, Niraj Bhattarai, Dr Bhuban Raj Kunwar				
501	Conf	Conflicts of interest				
502	Autho	ors declare no conflicts of interest.				
503	Fund	ing				
504	Autho	ors receive no funding for this study.				
505 506	Ethic The s	cs tudy was conducted from March 2021 to August 2021. Ethical approval was obtained				
507	from	the Institutional Review Committee [IRC] of BP Koirala Institute of Health Sciences				
508	[BPK	IHS], Dharan, dated 18 Feb 2021, with IRC No. Acd/597. An original copy of the ethical				
509	appro	val is submitted as supplementary files. Verbal consent was obtained from the				
510	partic	ipants, and the study maintained their anonymity.				
511						
512	Supporting Information					
513	S 1: C	Driginal copy of ethical approval from the Institutional Review Committee.				
514						
515 516	Refe	rences				
517						
518	1.	WHO. Global tuberculosis report 2019. Geneva: World Health Organization; 2019.				
519		Licence: CC BY-NC-SA 3.0 IGO. 2019.				
520	2.	Rock D. Tuberculosis: a global emergency. Work [Internet]. 1997;8(1):93–105.				
521		Available from:				
522		https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/WOR-				
523		1997-8111				
524	3.	World Health Organization. What is DOTS? A Guide to Understanding the WHO-				
525		recommended TB Control Strategy Known as DOTS. Prev Control [Internet]. 1999;1-				
526		39. Available from: https://apps.who.int/iris/handle/10665/65979				
527	4.	Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, et al.				
528		Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet				
529		[Internet]. 2019 Mar;393(10178):1331-84. Available from:				
530		https://linkinghub.elsevier.com/retrieve/pii/S0140673619300248				
531	5.	WHO. Follow-up to the high-level meetings of the UN General Assembly on health-				

532		related issues AMR Report by the Director-General. Seventy-second World Heal
533		Assem [Internet]. 2019;(April):1–11. Available from: https://amrcountryprogress.org.
534	6.	Tb D. Focus on Drug-resistant Tuberculosis. Glob Fund 2019 [Internet]. 2019;
535		Available from: https://www.theglobalfund.org/media/6651/publication_drug-
536		resistanttuberculosis_focuson_en.pdf?u=636450358380000000
537	7.	Law S, Piatek AS, Vincent C, Oxlade O, Menzies D. Emergence of drug resistance in
538		patients with tuberculosis cared for by the Indian health-care system: a dynamic
539		modelling study. Lancet Public Heal [Internet]. 2017;2(1):e47–55. Available from:
540		http://dx.doi.org/10.1016/S2468-2667(16)30035-4
541	8.	GON, MOHP, DOHS, NTCC. National Tuberculosis Program Nepal. NTCC, editor.
542		Vol. 75, Annual Report. Bhaktapur: NTC; 2018. 1–30 p.
543	9.	World Health Organization. Consolidated Guidelines on Tuberculosis Treatment.
544		Who. 2019.
545	10.	Ending TB: Invest Now or Pay Later. New Delhi: World Health Organization,
546		Regional Office for South-East Asia; 2018. Licence: CC BY-NC- SA 3.0 IGO. 2018;
547	11.	Hwang SS, Kang S, Lee JY, Lee JS, Kim HJ, Han SK, et al. Impact of outdoor air
548		pollution on the incidence of tuberculosis in the Seoul metropolitan area, South Korea.
549		Korean J Intern Med. 2014;29(2):183–90.
550	12.	WHO. ENDING TB IN SEAR, Regional strategic plan 2016-2020. Vol. 53, Journal of
551		Chemical Information and Modeling. 2013. 1689–1699 p.
552	13.	Institute of Health Metrix and Evaluations [IHME]. Findings from the Global Burden
553		of Disease Study 2017. Seattle, WA: IHME, 2018. Lancet. 2017;
554	14.	The Economist Intelligence Unit. It 's Time to End Drug-Resistant Tuberculosis. The
555		case for action. 2019;1–39. Available from:
556		http://www.eiu.com/graphics/marketing/pdf/its-time-to-end-drug-resistant-
557		tuberculosis-full-report.pdf
558	15.	Bhatia V, Srivastava R, Reddy KS, Sharma M, Mandal PP, Chhabra N, et al. Ending
559		TB in Southeast Asia: Current resources are not enough. BMJ Glob Heal. 2020;5(3):1-
560		11.
561	16.	Shrestha SK, Shah NP, Jha KK, Pant RP, Joshi LR, Bichha RP, et al. Challenges in the
562		diagnosis of drug-resistant tuberculosis by GeneXpert MTB/Rif in Nepal. SAARC J
563		Tuberc Lung Dis HIV/AIDS. 2018;16(2):8–15.
564	17.	Comolet T. La tuberculose à bacilles multi-résistants : défis d'une émergence globale.
565		Bull la Soc Pathol Exot. 2015;108(4):290-8.

566 18. Abdella K, Abdissa K, Kebede W, Abebe G. Drug resistance patterns of 567 Mycobacterium tuberculosis complex and associated factors among retreatment cases 568 around Jimma, Southwest Ethiopia. BMC Public Health [Internet]. 2015 Jul 2 [cited 569 2021 Mar 9];15(1):599. Available from: 570 http://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-015-1955-3 571 Ali MH, Alrasheedy AA, Hassali MA, Kibuule D, Godman B. Predictors of multidrug-19. 572 resistant tuberculosis (MDR-TB) in Sudan. Antibiotics. 2019 Sep 1;8(3). 573 20. Korotych O, Hovhannisyan A, Zaitseva O, Denisuk O, Dadu A, Dara M. Risk factors 574 associated with RR/MDR-TB among new pulmonary tuberculosis patients in urban and rural areas of Ukraine in 2017: retrospective analysis of routine surveillance data. 575 576 Public Heal Panor. 2019;5(4):536–47. 577 Liu L, Zhang X, Zhao L, Li N. Empirical analysis of the status and influencing factors 21. of catastrophic health expenditure of migrant workers in Western China. Int J Environ 578 Res Public Health. 2019;16(5):1-10. 579 Ismail N, Ismail F, Omar S V., Blows L, Gardee Y, Koornhof H, et al. Drug resistant 580 22. 581 tuberculosis in Africa: Current status, gaps and opportunities. Afr J Lab Med. 582 2018;7(2):1-11. 583 23. Li W Bin, Zhang YQ, Xing J, Ma ZY, Qu YH, Li XX. Factors associated with primary 584 transmission of multidrug-resistant tuberculosis compared with healthy controls in 585 Henan Province, China. Infect Dis Poverty [Internet]. 2015 Mar 24 [cited 2021 Mar 586 8];4(1):14. Available from: 587 https://idpjournal.biomedcentral.com/articles/10.1186/s40249-015-0045-1 Escombe AR, Oeser CC, Gilman RH, Navincopa M, Ticona E, Pan W, et al. Natural 588 24. 589 Ventilation for the Prevention of Airborne Contagion. PLOS Med [Internet]. 2007 590 [cited 2021 Mar 9];4(2):e68. Available from: 591 https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0040068 592 25. Shimeles E, Enquselassie F, Aseffa A, Tilahun M, Mekonen A, Wondimagegn G, et al. Risk factors for tuberculosis: A case-control study in Addis Ababa, Ethiopia. PLoS 593 594 One. 2019;14(4):1–18. 595 26. Mulu W, Mekonnen D, Yimer M, Admassu A, Abera B. Risk factors for multidrug resistant tuberculosis patients in amhara national regional state. Afr Health Sci. 596 597 2015;15(2):368-77. 598 27. Glasauer S, Altmann D, Hauer B, Brodhun B, Haas W, Perumal N. First-line 599 tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-

600		2017. PLoS One. 2019;14(6):2008-17.
601	28.	Gaude G, Hattiholli J, Kumar P. Risk factors and drug-resistance patterns among
602		pulmonary tuberculosis patients in northern Karnataka region, India. Niger Med J
603		[Internet]. 2014 [cited 2021 Mar 9];55(4):327. Available from:
604		http://www.nigeriamedj.com/text.asp?2014/55/4/327/137194
605	29.	Chuchottaworn C, Thanachartwet V, Sangsayunh P, Than TZM, Sahassananda D,
606		Surabotsophon M, et al. Risk Factors for Multidrug-Resistant Tuberculosis among
607		Patients with Pulmonary Tuberculosis at the Central Chest Institute of Thailand.
608		Munderloh UG, editor. PLoS One [Internet]. 2015 Oct 7 [cited 2021 Mar
609		9];10(10):e0139986. Available from:
610		https://dx.plos.org/10.1371/journal.pone.0139986
611	30.	Isaakidis P, Das M, Kumar AMV, Peskett C, Khetarpal M, Bamne A, et al. Alarming
612		levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai,
613		India. PLoS One. 2014 Oct 21;9(10):e110461.
614	31.	Baya B, Achenbach CJ, Kone B, Toloba Y, Dabitao DK, Diarra B, et al. Clinical risk
615		factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali. Int J Infect
616		Dis [Internet]. 2019 Apr 1 [cited 2021 Mar 9];81:149–55. Available from:
617		https://doi.org/10.1016/j.ijid.2019.02.004
618	32.	Eshetie S, Gizachew M, Dagnew M, Kumera G, Woldie H, Ambaw F, et al. Multidrug
619		resistant tuberculosis in Ethiopian settings and its association with previous history of
620		anti-tuberculosis treatment: A systematic review and meta-analysis. BMC Infect Dis.
621		2017 Mar 20;17(1).
622	33.	Su WJ, Feng JY, Huang CC, Perng RP. Increasing drug resistance of Mycobacterium
623		tuberculosis isolates in a medical center in northern Taiwan. J Formos Med Assoc.
624		2008 Mar 1;107(3):259–64.
625	34.	B S, A S. Contributing Factors Associated with Multi-Drugs Resistance Tuberculosis
626		among MDR-TB Clients of Kathmandu, Nepal. Int J Heal Sci Res. 2017;7(july):164-
627		70.
628	35.	Khan MS, Hutchison C, Coker RJ, Yoong J, Hane KM, Innes AL, et al. Preventing
629		emergence of drug resistant tuberculosis in Myanmar's transitioning health system.
630		Health Policy Plan. 2017;32:ii43–50.
631	36.	Hirpa S, Medhin G, Girma B, Melese M, Mekonen A, Suarez P, et al. Determinants of
632		multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis
633		Ababa: A case control study. BMC Public Health. 2013;13(1):1–9.

Gobena D, Ameya G, Haile K, Abreha G, Worku Y, Debela T. Predictor of multidrug
resistant tuberculosis in southwestern part of Ethiopia: A case control study. Ann Clin
Microbiol Antimicrob. 2018 Jul 3;17(1).

- 637 38. Moyo S, Cox HS, Hughes J, Daniels J, Synman L, De Azevedo V, et al. Loss from
 638 treatment for drug resistant tuberculosis: Risk factors and patient outcomes in a
 639 community-based program in khayelitsha, South Africa. PLoS One. 2015;10(3):1–13.
- 640 39. Demile B, Zenebu A, Shewaye H, Xia S, Guadie A. Risk factors associated with
 641 multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and
 642 teaching hospital, Ethiopia. BMC Infect Dis. 2018 May 31;18(1).
- 40. Workicho A, Kassahun W, Alemseged F. Risk factors for multidrug-resistant
 tuberculosis among tuberculosis patients: A case-control study. Infect Drug Resist.

645 2017 Mar 13;10:91–6.

- Mulu W, Mekonnen D, Yimer M, Admassu A, Abera B. Risk factors for multidrug
 resistant tuberculosis patients in amhara national regional state. Afr Health Sci
 [Internet]. 2015 [cited 2021 Mar 9];15(2):368–77. Available from:
- 649 /pmc/articles/PMC4480497/
- 650 42. Guenaoui K, Harir N, Ouardi A, Zeggai S, Sellam F, Bekri F, et al. Use of GeneXpert
- Mycobacterium tuberculosis/rifampicin for rapid detection of rifampicin resistant
 Mycobacterium tuberculosis strains of clinically suspected multi-drug resistance
 tuberculosis cases. Ann Transl Med. 2016 May 1;4(9):168.
- 43. Stosic M, Vukovic D, Babic D, Antonijevic G, Foley KL, Vujcic I, et al. Risk factors
 for multidrug-resistant tuberculosis among tuberculosis patients in Serbia: A casecontrol study. BMC Public Health [Internet]. 2018 Sep 12 [cited 2021 Mar
- 657 9];18(1):1114. Available from:
- https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-018-6021-5
- Mesfin EA, Beyene D, Tesfaye A, Admasu A, Addise D, Amare M, et al. Drugresistance patterns of mycobacterium tuberculosis strains and associated risk factors
 among multi drug-resistant tuberculosis suspected patients from Ethiopia. PLoS One.
 2018;13(6):1–16.
- 663 45. Baral SC, Aryal Y, Bhattrai R, King R, Newell JN. The importance of providing
 664 counselling and financial support to patients receiving treatment for multi-drug
 665 resistant TB: Mixed method qualitative and pilot intervention studies. BMC Public
- 666 Health [Internet]. 2014 Jan 17 [cited 2021 Mar 15];14(1):46. Available from:
- 667 http://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-14-46

668	46.	Tang S, Tan S, Yao L, Li F, Li L, Guo X, et al. Risk factors for poor treatment
669		outcomes in patients with MDR-TB and XDR-TB in China: Retrospective multi-center
670		investigation. PLoS One. 2013;8(12):1-8.
671	47.	Zhang C, Wang Y, Shi G, Han W, Zhao H, Zhang H, et al. Determinants of multidrug-
672		resistant tuberculosis in Henan province in China: a case control study. BMC Public
673		Health. 2016 Jan 16;16(1):42.
674	48.	Welekidan LN, Skjerve E, Dejene TA, Gebremichael MW, Brynildsrud O, Agdestein
675		A, et al. Characteristics of pulmonary multidrug-resistant tuberculosis patients in
676		Tigray Region, Ethiopia: A cross-sectional study. Quinn F, editor. PLoS One
677		[Internet]. 2020 Aug 14 [cited 2021 Mar 9];15(8):e0236362. Available from:
678		https://dx.plos.org/10.1371/journal.pone.0236362
679	49.	Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, Velez-Segovia E, Soria-
680		Montoya A, Nuñez-Garbin A, et al. Factors associated with anti-tuberculosis
681		medication adverse effects: A case-control study in Lima, Peru. PLoS One.
682		2011;6(11):1–5.
683	50.	Elduma AH, Mansournia MA, Foroushani AR, Ali HMH, Elegail AMA, Elsony A, et
684		al. Assessment of the risk factors associated with multidrug-resistant tuberculosis in
685		Sudan: a case-control study. Epidemiol Health. 2019;41:e2019014.
686	51.	Bichha RP, Jha KK, Salhotra VS, Weerakoon AP, Karki KB, Bichha N. An
687		Epidemiological Study to Find out Risk Factors of Multi Drugs Resistance
688		Tuberculosis in Nepal. SAARC J Tuberc Lung Dis HIV/AIDS. 2018;14(2):31-8.
689	52.	Hirama T, Sabur N, Derkach P, McNamee J, Song H, Marras T, et al. Risk factors for
690		drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010-
691		2016. Canada Commun Dis Rep. 2020 Apr 2;46(04):84–92.
692		
693		
694		